Immediate Impact

1 by Nobel laureates 1 from Science/Nature 98 standout
Sub-graph 1 of 15

Citing Papers

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
2024 Standout

Works of David Preiss being referenced

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2019 Standout
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy
2011 Standout

Author Peers

Author Last Decade Papers Cites
David Preiss 4176 3180 2052 103 8.1k
D. J. Betteridge 4158 3442 2281 141 9.6k
John Fuller 4951 3050 2679 98 11.0k
Gérald Luc 2544 3067 2947 87 8.9k
Marshall B. Elam 3194 3619 1540 82 7.1k
Jiří Fröhlich 3644 4586 2241 160 9.8k
Pekka Koskinen 3416 3568 2535 69 7.4k
Hanna E. Bloomfield 3767 4601 2002 81 8.3k
Sergio Fazio 2197 4418 1845 141 7.7k
Vasilios G. Athyros 4026 3843 2560 273 10.2k
Russell Scott 5727 4665 1837 237 11.1k

All Works

Loading papers...

Rankless by CCL
2026